NeurAxis, Inc. announced a stock dividend on its Series B Preferred Stock on April 10 2026. The board authorized the issuance of 510,605 shares of common stock, with each preferred share entitled to one common share for every $2.38 of accrued and unpaid dividends. The dividend will be paid on April 28 2026, with a record date of April 21 2026. Holders of fractional preferred shares will receive cash equal to $2.38 multiplied by the fractional amount.
The dividend represents a material financing event for NeurAxis. By converting accrued preferred dividends into common equity, the company increases its share count while preserving cash, a strategy often used when cash resources are limited or when management wishes to avoid a cash payout that could strain liquidity. The move also signals the company’s intent to reward preferred shareholders while maintaining flexibility for future capital needs. The issuance of new common shares will dilute existing common shareholders, but the dilution is modest relative to the company’s total equity base.
NeurAxis’s financial context underscores the rationale for a stock dividend. In FY 2025 the company generated $3.6 million in revenue, up 33 % YoY, but recorded a net loss of $7.8 million, reflecting ongoing investment in product development and regulatory approvals. Cash balances stood at $4.97 million against $426 k in debt, giving the company a modest liquidity cushion but limited capacity for large cash distributions. The decision to issue a stock dividend rather than a cash payout aligns with the company’s strategy to conserve cash while still providing a return to preferred investors.
The dividend also impacts NeurAxis’s capital structure. Prior to the dividend, the company had issued approximately $5 million of Series B Convertible Preferred Stock in November 2024, with a stated value of $2.38 per share. The new dividend will increase the number of common shares outstanding, potentially lowering the debt‑to‑equity ratio and improving leverage metrics. However, the additional shares will also dilute earnings per share for common shareholders, a trade‑off that management has deemed acceptable given the company’s current cash position and growth trajectory.
NeurAxis’s broader business focus remains on neuromodulation therapies, notably its IB‑Stim® technology for functional abdominal pain and dyspepsia. Recent milestones include FDA clearance for functional dyspepsia treatment and a Veterans Affairs Federal Supply Schedule contract, positioning the company for future revenue growth. The stock dividend, while dilutive, is part of a broader strategy to balance shareholder returns with the need to fund ongoing clinical and regulatory activities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.